TickerFacts.

Nkarta, Inc. (NKTX): Net Income

Annual figures by period end, from SEC filings.

-$104.08M
Year ended 2025-12-31
-$117.32M
Trailing 12 months to 2026-06-30
2019-12-31: -$21.08M2020-12-31: -$91.36M2021-12-31: -$86.08M2022-12-31: -$113.84M2023-12-31: -$117.50M2024-12-31: -$108.79M2025-12-31: -$104.08M-$104.08M
2019-12-31 Net Income (USD) 2025-12-31
Period endedNet IncomeChange YoYSource filing
2025-12-31-$104.08Mn/m2026-03-25, From 2025-01-01
2024-12-31-$108.79Mn/m2026-03-25, From 2024-01-01
2023-12-31-$117.50Mn/m2025-03-26, From 2023-01-01
2022-12-31-$113.84Mn/m2024-03-21, From 2022-01-01
2021-12-31-$86.08Mn/m2023-03-16, From 2021-01-01
2020-12-31-$91.36Mn/m2022-03-17, From 2020-01-01
2019-12-31-$21.08Mn/a2021-03-25, From 2019-01-01

Net Income at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedNet IncomeChange YoY
Nkarta, Inc. (NKTX)2025-12-31-$104.08Mn/m
Abbott Laboratories (ABT)2025-12-31$6.52B-51.3%
Bristol Myers Squibb Co (BMY)2025-12-31$7.05Bn/m
TherapeuticsMD, Inc. (TXMD)2025-12-31-$569.0Kn/m
Eli Lilly & Co (LLY)2025-12-31$20.64B+94.9%
Pfizer Inc (PFE)2025-12-31$7.77B-3.2%
Johnson & Johnson (JNJ)2025-12-28$26.80B+90.6%
Nature's Sunshine Products Inc (NATR)2025-12-31$20.45M+159.1%
Merck & Co., Inc. (MRK)2025-12-31$18.25B+6.6%

Compare NKTX, ABT, BMY, TXMD side by side · Screen every company in Pharmaceutical Preparations ↗